Combining the HER2 CAR with GD2 CAR, CD276 CAR in combination with anti-CD47 antibody therapy may prove to be sufficiently potent to eradicate DIPG tumor cells in the brain and warrants further investigation. Here, CD47 is linked to neoplasm.